Podocytopathies.
This Nature Reviews Disease Primers review reframes podocytopathies around the mechanism of podocyte injury rather than the biopsy pattern, arguing that a single aetiology-based classification can replace the historically separate paediatric (response-based) and adult (histology-based) schemes and guide more personalised, lower-steroid treatment.
Background
Podocytopathies are glomerular diseases in which initial podocyte injury or dysfunction leads to proteinuria and often nephrotic syndrome. The term covers a set of characteristic histological patterns — most commonly focal segmental glomerulosclerosis, minimal change, membranous nephropathy, diffuse mesangial sclerosis and collapsing glomerulopathy. In practice, however, proteinuria of glomerular origin is frequently managed without a biopsy; when the protein lost is mostly albumin, that loss is a direct readout of podocyte injury and a strong predictor of cardiovascular events, kidney failure and reduced survival.
Key findings
The authors set out a unifying, mechanism-based view: podocytopathies arise from autoimmune, genetic, mechanical (hyperfiltration), infectious, toxic or monoclonal mechanisms, which may coexist in the same patient and vary by age. That framing bridges the historically divergent paediatric classification (based on treatment response) and the adult one (based on histology). Clinically, patients present with oedema and volume disturbances and are at risk of thromboembolism, serious infections and progressive kidney dysfunction.
Diagnosis
Diagnosis integrates clinical features with emerging serology for podocyte-directed autoantibodies, targeted genetic testing, and kidney biopsy where it is still required. The review's central point about workup is that it must delineate the cause of podocyte dysfunction, not merely name the histological pattern — the cause is what determines which therapy is appropriate.
Clinical implications
Management combines supportive care with aetiology-guided therapy aimed at minimising steroid exposure and preventing relapses. The authors argue that current advances in the field, and their effect on diagnostic and therapeutic algorithms, open a path towards personalised use of both traditional treatments and newly available drugs, with the expectation of improved outcomes and quality of life for patients with podocytopathies.
Category
KDIGO
Source
Nat Rev Dis Primers
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.